home / stock / alks / alks articles
On Tuesday, Alkermes plc (NASDAQ:ALKS) revealed topline results from the narcolepsy type 2 (NT2) and idiopathic hypersomnia (IH) cohorts ...
Understanding Value Stocks A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's futu...
— Alkermes Emerges as Pure-Play, Profitable Neuroscience Company — — Alkermes Provides Updated Financial Expectations for 2023 ??...
Alkermes PLC (NASDAQ: ALKS) reported Q3 FY23 adjusted EPS of $0.64 compared to $0.02 a year ago, beating the consensus of $0.43. The comp...
U.S. stocks traded mixed, with the Dow Jones falling around 10 points on Wednesday. Here are some big stocks recording gains in today’s sessi...
News, Short Squeeze, Breakout and More Instantly...
Alkermes plc Company Name:
ALKS Stock Symbol:
NASDAQ Market:
Alkermes Announces Initiation of Vibrance-1 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Narcolepsy Type 1 PR Newswire DUBLIN , April 24, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced initiation of the Vibrance-1 study, a pha...
Alkermes to Report First Quarter Financial Results on May 1, 2024 PR Newswire DUBLIN , April 17, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET ( 1:00 p.m. BST ) on Wednesday, Ma...
2024-04-10 09:00:04 ET Akash Tewari from Jefferies issued a price target of $50.00 for ALKS on 2024-04-10 07:44:00. The adjusted price target was set to $50.00. At the time of the announcement, ALKS was trading at $26.73. The overall price target consensus is at $31.33 w...